1.Factors Affecting the Variation of Maximum Speech Intelligibility in Patients With Sensorineural Hearing Loss Other Than Apparent Retrocochlear Lesions.
Izumi YAHATA ; Tetsuaki KAWASE ; Hiromitsu MIYAZAKI ; Yusuke TAKATA ; Daisuke YAMAUCHI ; Kazuhiro NOMURA ; Yukio KATORI
Clinical and Experimental Otorhinolaryngology 2015;8(3):189-193
OBJECTIVES: To examine the relationship between speech intelligibilities among the similar level of hearing loss and threshold elevation of the auditory brainstem response (ABR). METHODS: The relationship between maximum speech intelligibilities among similar levels of hearing loss and relative threshold elevation of the click-evoked ABR (ABR threshold - pure tone average at 2,000 and 4,000 Hz) was retrospectively reviewed in patients with sensorineural hearing loss (SNHL) other than apparent retrocochlear lesions as auditory neuropathy, vestibular schwannoma and the other brain lesions. RESULTS: Comparison of the speech intelligibilities in subjects with similar levels of hearing loss found that the variation in maximum speech intelligibility was significantly correlated with the threshold elevation of the ABR. CONCLUSION: The present results appear to support the idea that variation in maximum speech intelligibility in patients with similar levels of SNHL may be related to the different degree of dysfunctions of the inner hair cells and/or cochlear nerves in addition to those of outer hair cells.
Brain
;
Cochlear Nerve
;
Evoked Potentials, Auditory, Brain Stem
;
Hair
;
Hearing Loss
;
Hearing Loss, Sensorineural*
;
Humans
;
Neurilemmoma
;
Retrospective Studies
;
Speech Intelligibility*
;
Vestibular Neuronitis
2.Effects of Metoclopramide on Esophageal Motor Activity and Esophagogastric Junction Compliance in Healthy Volunteers.
Hironobu MIKAMI ; Norihisa ISHIMURA ; Kousuke FUKAZAWA ; Mayumi OKADA ; Daisuke IZUMI ; Shino SHIMURA ; Eiko OKIMOTO ; Masahito AIMI ; Shunji ISHIHARA ; Yoshikazu KINOSHITA
Journal of Neurogastroenterology and Motility 2016;22(1):112-117
BACKGROUND/AIMS: Prokinetic drugs such as metoclopramide are frequently used as second-line therapy for patients with gastroesophageal reflux disease. However, their beneficial effects remain unclear. Esophageal motor activities and compliance of the esophagogastric junction (EGJ) are important for prevention of gastroesophageal reflux. Although metoclopramide has been reported to increase lower esophageal sphincter (LES) pressure, its effects on EGJ compliance have not been evaluated. In the present study, we investigated the effects of metoclopramide on esophageal motor activities and EGJ compliance. METHODS: Nine healthy male volunteers without abdominal symptoms were enrolled. Peristaltic esophageal contractions and LES pressure were examined using high-resolution esophageal manometry, while EGJ compliance was evaluated with an endoluminal functional lumen-imaging probe. After obtaining baseline values for esophageal motor activities and EGJ compliance, metoclopramide (10 mg) was intravenously administered, then all measurements were repeated at 15 minutes after administration in each subject. RESULTS: Following administration of metoclopramide, mean resting LES pressure was significantly increased as compared with the baseline (13.7 +/- 9.2 vs 26.7 +/- 8.8 mmHg, P < 0.05). In addition, metoclopramide significantly augmented peristaltic contractions, especially in the distal esophageal segment (P < 0.05). On the other hand, distensibility index did not change after administration (4.5 +/- 0.5 vs 4.1 +/- 0.5 mm2/mmHg), suggesting no significant effect of metoclopramide on EGJ compliance. CONCLUSIONS: Metoclopramide augmented esophageal contractions without changing EGJ compliance in healthy adults.
Adult
;
Compliance*
;
Esophageal Sphincter, Lower
;
Esophagogastric Junction*
;
Gastroesophageal Reflux
;
Hand
;
Healthy Volunteers*
;
Humans
;
Male
;
Manometry
;
Metoclopramide*
;
Motor Activity*
;
Volunteers
3.Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
Moito IIJIMA ; Noriyuki OKONOGI ; Nakako Izumi NAKAJIMA ; Yukie MOROKOSHI ; Hiroaki KANDA ; Taiju YAMADA ; Yusuke KOBAYASHI ; Kouji BANNO ; Masaru WAKATSUKI ; Shigeru YAMADA ; Tadashi KAMADA ; Daisuke AOKI ; Sumitaka HASEGAWA
Journal of Gynecologic Oncology 2020;31(2):19-
OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was to investigate the effects of carbon-ion (C-ion) beam irradiation on PD-L1 expression in human uterine cervical adeno/adenosquamous carcinoma (UCAA) cells and clinical samples and to identify the prognostic factors for outcomes after C-ion radiotherapy (CIRT).METHODS: The effects of C-ion irradiation on PD-L1 expression in human UCAA and cervical squamous cell carcinoma cells were examined by flow cytometry. We examined PD-L1 expression in UCAA biopsy specimens from 33 patients before CIRT started (pre-CIRT) and after 12 Gy (relative biological effectiveness [RBE]) irradiation (post-12Gy-C) in 4 fractions of CIRT to investigate the correlation between PD-L1 status and clinical outcomes.RESULTS: The PD-L1 expression was upregulated by C-ion beam in a dose-dependent manner in HeLa and SiHa cells through phosphorylated Chk1. The overall frequencies of pre-CIRT and post-12Gy-C PD-L1 positivity were 45% (15/33) and 67% (22/33), respectively. The post-12Gy-C PD-L1 expression was significantly elevated compared to the pre-CIRT PD-L1 expression. There was no significant relationship between the pre-CIRT PD-L1 status and clinical outcomes, such as local control (LC), progression-free survival (PFS), and overall survival (OS). However, the post-12Gy-C PD-L1 expression had better correlation with PFS, but not with LC and OS.CONCLUSION: CIRT can induce PD-L1 expression in UCAA and we propose that PD-L1 expression after starting CIRT may become as a predictive prognostic marker in CIRT for UCAA.
Antigens, CD274
;
Biopsy
;
Carcinoma, Squamous Cell
;
Disease-Free Survival
;
Flow Cytometry
;
Heavy Ion Radiotherapy
;
Humans
;
Radiotherapy
;
Treatment Outcome
;
Uterine Cervical Neoplasms
4.Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
Moito IIJIMA ; Noriyuki OKONOGI ; Nakako Izumi NAKAJIMA ; Yukie MOROKOSHI ; Hiroaki KANDA ; Taiju YAMADA ; Yusuke KOBAYASHI ; Kouji BANNO ; Masaru WAKATSUKI ; Shigeru YAMADA ; Tadashi KAMADA ; Daisuke AOKI ; Sumitaka HASEGAWA
Journal of Gynecologic Oncology 2020;31(2):e19-
OBJECTIVE:
Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was to investigate the effects of carbon-ion (C-ion) beam irradiation on PD-L1 expression in human uterine cervical adeno/adenosquamous carcinoma (UCAA) cells and clinical samples and to identify the prognostic factors for outcomes after C-ion radiotherapy (CIRT).
METHODS:
The effects of C-ion irradiation on PD-L1 expression in human UCAA and cervical squamous cell carcinoma cells were examined by flow cytometry. We examined PD-L1 expression in UCAA biopsy specimens from 33 patients before CIRT started (pre-CIRT) and after 12 Gy (relative biological effectiveness [RBE]) irradiation (post-12Gy-C) in 4 fractions of CIRT to investigate the correlation between PD-L1 status and clinical outcomes.
RESULTS:
The PD-L1 expression was upregulated by C-ion beam in a dose-dependent manner in HeLa and SiHa cells through phosphorylated Chk1. The overall frequencies of pre-CIRT and post-12Gy-C PD-L1 positivity were 45% (15/33) and 67% (22/33), respectively. The post-12Gy-C PD-L1 expression was significantly elevated compared to the pre-CIRT PD-L1 expression. There was no significant relationship between the pre-CIRT PD-L1 status and clinical outcomes, such as local control (LC), progression-free survival (PFS), and overall survival (OS). However, the post-12Gy-C PD-L1 expression had better correlation with PFS, but not with LC and OS.
CONCLUSION
CIRT can induce PD-L1 expression in UCAA and we propose that PD-L1 expression after starting CIRT may become as a predictive prognostic marker in CIRT for UCAA.
5.Identification and International Comparison of Drugs Contraindicated for Pregnant Women in the Package Inserts
Takamasa SAKAI ; Yuri SATO ; Shiro HATAKEYAMA ; Daisuke KIKUCHI ; Masami TSUCHIYA ; Yuki KONDO ; Izumi SATO ; Yuko OKADA ; Taku OBARA
Japanese Journal of Drug Informatics 2024;25(4):211-219
Objective: The package inserts are official clinical decision-making documents that provide pharmacological treatment information. However, it has been noted that package inserts on perinatal drug usage differ greatly from expert opinions. This study identified Japanese package insert drugs that are contraindicated for pregnant women and compared them to foreign risk categories.Methods: The survey included 19,022 drugs on the drug pricing list as of April 2022, with package inserts available on the Pharmaceuticals and Medical Devices Agency website. We retrieved the package inserts with the word “pregnant” in the “Contraindications” section and reviewed the descriptions to exclude those that satisfied the exclusion criteria. We also checked the foreign risk categories of contraindicated ingredients for pregnant women. This study used the Australian Therapeutic Goods Administration’s categorization for prescribing medicines in pregnancy (the TGA classification).Results: Of the 19,022 medicines studied, 4,111 (21.6%) were contraindicated for pregnant women. Conversely, 19 (5.1%) ingredients categorized under the relatively safe TGA classifications A, B1, and B2 were also contraindicated for pregnant Japanese women.Conclusion: This study revealed that Japanese package inserts contraindicate over 20% of drugs for pregnant women. On the other hand, some forbidden ingredients did not match the foreign risk categories. Therefore, healthcare professionals should be aware of the limitations of Japanese package inserts concerning pregnant women and make careful decisions based on both package inserts and additional drug information.
6.Appendix 1
Masao IWAGAMI ; Kotonari AOKI ; Manabu AKAZAWA ; Chieko ISHIGURO ; Shinobu IMAI ; Nobuhiro OOBA ; Makiko KUSAMA ; Daisuke KOIDE ; Atsushi GOTO ; Norihiro KOBAYASHI ; Izumi SATO ; Sayuri NAKANE ; Makoto MIYAZAKI ; Kiyoshi KUBOTA
Japanese Journal of Pharmacoepidemiology 2018;23(2):124-124
7.Appendix 2
Masao IWAGAMI ; Kotonari AOKI ; Manabu AKAZAWA ; Chieko ISHIGURO ; Shinobu IMAI ; Nobuhiro OOBA ; Makiko KUSAMA ; Daisuke KOIDE ; Atsushi GOTO ; Norihiro KOBAYASHI ; Izumi SATO ; Sayuri NAKANE ; Makoto MIYAZAKI ; Kiyoshi KUBOTA
Japanese Journal of Pharmacoepidemiology 2018;23(2):125-130
8.Appendix 3
Masao IWAGAMI ; Kotonari AOKI ; Manabu AKAZAWA ; Chieko ISHIGURO ; Shinobu IMAI ; Nobuhiro OOBA ; Makiko KUSAMA ; Daisuke KOIDE ; Atsushi GOTO ; Norihiro KOBAYASHI ; Izumi SATO ; Sayuri NAKANE ; Makoto MIYAZAKI ; Kiyoshi KUBOTA
Japanese Journal of Pharmacoepidemiology 2018;23(2):131-139
9.Appendix 4
Masao IWAGAMI ; Kotonari AOKI ; Manabu AKAZAWA ; Chieko ISHIGURO ; Shinobu IMAI ; Nobuhiro OOBA ; Makiko KUSAMA ; Daisuke KOIDE ; Atsushi GOTO ; Norihiro KOBAYASHI ; Izumi SATO ; Sayuri NAKANE ; Makoto MIYAZAKI ; Kiyoshi KUBOTA
Japanese Journal of Pharmacoepidemiology 2018;23(2):140-143
10.Appendix 5
Masao IWAGAMI ; Kotonari AOKI ; Manabu AKAZAWA ; Chieko ISHIGURO ; Shinobu IMAI ; Nobuhiro OOBA ; Makiko KUSAMA ; Daisuke KOIDE ; Atsushi GOTO ; Norihiro KOBAYASHI ; Izumi SATO ; Sayuri NAKANE ; Makoto MIYAZAKI ; Kiyoshi KUBOTA
Japanese Journal of Pharmacoepidemiology 2018;23(2):144-146